MedTrace Logo

Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region

NCT07017803 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 460

Last updated 2025-06-12

No results posted yet for this study

Summary

Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures. This is highlighted by the emergence of mutations encoding resistance to bed aquiline and quinolones which may impact the roll out of the newly recommended Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (BPaLM) regimens.

It is also worth noting that there is increasing evidence of the significance of TB lineage in the outcome of infection, the approach in the study will provide both information on chains of transmission and lineage.

Conditions

  • Tuberculosis, Multi Drug Resistant
  • Strains
  • Molecular Epidemiology
  • Multi Drug Resistant Tuberculosis
  • Central Africa

Sponsors & Collaborators

  • Fondation Congolaise pour la Recherche Médicale

    collaborator UNKNOWN

  • Centre Pasteur du Cameroun

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Centre de Recherche Médicale de Lambaréné

    lead OTHER

Principal Investigators

  • Ayôla Akim ADEGNIKA · Centre de Recherches Medicales de Lambarene

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-11-30
Completion
2026-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07017803 on ClinicalTrials.gov